KEYNOTE-775: Lenvatinib/Pembrolizumab in Patients with Advanced Endometrial Carcinoma
Robert Holloway, MD, review safety and efficacy data from a clinical trial investigation of lenvatinib combined with pembrolizumab for the treatment of advanced endometrial cancer.
EP: 1.Case Overview: A 71-Year-Old Woman with Metastatic Endometrial Cancer
EP: 2.Presentation of Endometrial Cancer and MMR Testing
EP: 3.Available Systemic Therapy Options for Patients with MMR-Proficient Metastatic Endometrial Cancer
EP: 4.KEYNOTE-775: Lenvatinib/Pembrolizumab in Patients with Advanced Endometrial Carcinoma
EP: 5.Selecting an Appropriate Second-Line Treatment for Metastatic Endometrial Cancer
EP: 6.Second-Line Treatment Goals and Adverse Event Management for Patients with Metastatic Endometrial Cancer
EP: 7.Racial Disparities and Unmet Needs in Endometrial Cancer
Case History
June 2021
A 71-year-old postmenopausal woman presented with intermittent uterine bleeding, increased urinary frequency, and cramping over the past 6 months.
- She noted that she underwent menopause at 52 years of age
- She is married and has 2 adult children
- PMH: T1D since childhood, well-controlled
- PE: Notable for uterine tenderness upon palpation
- ECOG PS= 1
- Chest/abdomen/pelvis CT revealed uterine and bladder masses
- CA-125= 38.6 U/mL
- Endometrial biopsy results:
- Endometrioid adenocarcinoma
- FIGO stage IVA
- Grade 3 (poorly differentiated)
- IHC testing revealed mismatch repair proficiency (pMMR) and estrogen receptor (ER) negativity
July 2021:
- Patient started carboplatin/paclitaxel (6 cycles), which was well-tolerated
- Patient was scheduled for follow-up visits every 3 months after completion
May 2022 (6 months post–chemotherapy completion):
- CA-125 level increased to 42.1 U/mL
- CT revealed that the previous bladder metastatic mass increased slightly in size
- The patient discussed targeted systemic therapy options with her clinician, and she expressed the desire to spend as much time as possible with her grandchildren.
- They jointly decided to trial lenvatinib/pembrolizumab, with instructions to continue follow-up visits every 3 months.
FDA Accepts sBLA of Dostarlimab/Chemo to Include All Advanced Endometrial Cancer
April 24th 2024The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.
Read More
Roundtable Roundup: Surveying Oncologists on Endometrial Cancer Treatment
March 27th 2024Bhavana Pothuri, MD, and Krishnansu S. Tewari, MD, discussed the treatment options of a patient with advanced endometrial cancer and participants chose an immune checkpoint inhibitor to use for therapy.
Read More
